Abstract
Background: Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine.
Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses.
Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups.
Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster.
Funding: School of Medicine, UC-Chile and ANID.ClinicalTrials.gov ID: NCT05124509 .
Keywords: BNT162b2; COVID-19; CoronaVac; SARS-CoV-2; Solid organ transplant; Vaccine; Vaccine immunogenicity.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, CoronaVac, BNT162b2, vaccine immunogenicity., solid organ transplant, 【초록키워드】 BNT162b2 vaccine, vaccination, mRNA vaccine, outcome, anti-SARS-CoV-2, SARS-CoV-2 vaccine, cohort study, kidney, Medicine, IgG antibody, mRNA, neutralising antibody, Prospective, Patient, age, School, humoral immune response, General population, women, T-cell, homologous, Care, liver, Heterologous, booster, T-cell responses, inactivated, IFN-γ, IL-2, dose, heterologous vaccine, solid organ, SOT, recipients, end point, priming, recipient, effective, secondary, not differ, significantly, proportion, median, determine, significantly higher, groups, secreting, All participant, more difficult, of BNT162b2, Red, 【제목키워드】 prospective cohort study, SARS-CoV-2 vaccine, mRNA, booster, inactivated, recipient,